论文部分内容阅读
胃癌是最常见的恶性肿瘤之一,手术切除是胃癌首选的治疗方法,但由于缺乏典型早期症状,多数患者就诊时已有远处转移,失去手术治疗的机会。目前,晚期胃癌的治疗主要是以化疗联合靶向治疗为主的综合治疗。过去几十年,随着肿瘤生物学的快速发展以及肿瘤分子标志物的不断涌现,使众多靶向药物应运而生,如表皮生长因子(EGFR)、血管生成、免疫关键位点阻滞剂、细胞周期、细胞凋亡、关键酶、C-MET、m TOP等信号通路,以及胰岛素样生长因子受体(IGF-IR)等。分子靶向药物作用机制的深入研究将为胃癌的治疗提供新的认识。
Gastric cancer is one of the most common malignant tumors. Surgical resection is the preferred treatment for gastric cancer. However, due to the lack of typical early symptoms, most patients have had distant metastases and lost the chance of surgical treatment. At present, the treatment of advanced gastric cancer is mainly based on chemotherapy combined with targeted therapies based comprehensive treatment. Over the past few decades, with the rapid development of tumor biology and the continuous emergence of tumor molecular markers, many targeted drugs have emerged, such as epidermal growth factor (EGFR), angiogenesis, immune critical site blockers, Cell cycle, apoptosis, key enzymes, C-MET, m TOP and other signaling pathways, as well as insulin-like growth factor receptor (IGF-IR) and so on. In-depth study of the molecular mechanisms of action of targeted drugs will provide new insights into the treatment of gastric cancer.